克罗恩病患者中阿达木单抗诱导黏膜愈合相关的临床与药代动力学因素
该研究为一项随机对照试验的事后分析,纳入中度至重度活动性克罗恩病患者,比较阿达木单抗单药组(n=85)与联合硫唑嘌呤组(n=91)的简易内镜评分。第26周联合组内镜应答的比值比显著高于单药组(OR 2.12,95%CI 1.04-4.32),第52周无显著差异;第26周阿达木单抗谷浓度较高与第52周黏膜愈合相关(OR 1.34,95%CI 1.14-1.58;趋势P=.001)。
要点
- 第26周联合组内镜应答的比值比显著高于单药组(OR 2.12,95%CI 1.04-4.32)。
- 第0周简易内镜评分与第26周黏膜愈合相关(OR 0.80,95%CI 0.72-0.90)。
- 第26周阿达木单抗谷浓度较高与第52周黏膜愈合相关(OR 1.34,95%CI 1.14-1.58)。
核心结论
- 在中度至重度克罗恩病患者中,阿达木单抗联合硫唑嘌呤可提高阿达木单抗谷浓度,较高的谷浓度与第26周和第52周的内镜应答及黏膜愈合相关。
研究设计与样本
- 本研究为一项前瞻性随机对照试验的事后分析,比较阿达木单抗单药组(n=85)与阿达木单抗联合硫唑嘌呤组(n=91),于2011年6月至2014年6月在日本开展。
- 最终纳入来自44个转诊中心的第26周135例和第52周139例患者进行分析。
主要发现
- 第26周联合组内镜应答的比值比显著高于单药组(OR 2.12,95%CI 1.04-4.32),第52周两组无显著差异(OR 1.50,95%CI 0.77-2.94)。
- 第26周和第52周两组黏膜愈合的比值比无显著差异。
- 第0周简易内镜评分与第26周黏膜愈合相关(OR 0.80,95%CI 0.72-0.90),与第52周黏膜愈合相关(OR 0.91,95%CI 0.84-0.99)。
- 第26周较高的阿达木单抗谷浓度与第52周黏膜愈合相关(OR 1.34,95%CI 1.14-1.58;趋势P=.001)。
- 第26周和第52周有内镜应答患者的阿达木单抗谷浓度显著高于无内镜应答患者(P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We previously reported results from a prospective randomized controlled trial comparing the efficacy of adalimumab monotherapy versus combination with azathioprine for patients with Crohn's disease (CD) who were naive to biologics and thiopurines. We performed a subanalysis of data from this study to evaluate factors associated with endoscopic response and mucosal healing in study participants. METHODS: We compared simple endoscopic scores for CD between patients with moderate to severe active CD randomly assigned groups that received adalimumab monotherapy (n = 85) or adalimumab in combination with azathioprine (n = 91), from June 2011 to June 2014 in Japan. We evaluated associations of simple endoscopic scores for CD with clinical factors and trough levels of adalimumab. Ultimately, 135 patients at Week 26 and 139 patients at Week 52 from 44 referral sites were analyzed for the present investigation. RESULTS: The odds for endoscopic response were significantly higher in the combination group than in the monotherapy group at Week 26 (odds ratio [OR], 2.12; 95% confidence interval [CI], 1.04-4.32) but not at Week 52 (OR, 1.50; 95% CI, 0.77-2.94). The odds of mucosal healing did not differ significantly between groups at Weeks 26 or 52. Simple endoscopic scores for CD at Week 0 was significantly associated with mucosal healing at Week 26 (OR, 0.80; 95% CI, 0.72-0.90) and at Week 52 (OR, 0.91; 95% CI, 0.84-0.99). Higher adalimumab trough level at Week 26 associated with mucosal healing at Week 52 (OR, 1.34; 95% CI, 1.14-1.58; P for trend = .001) and was significantly higher in patients with endoscopic response than in patients without endoscopic response at Weeks 26 and 52 (P < .001). CONCLUSIONS: In a post hoc analysis of data from a randomized controlled trial of patients with moderate to severe CD, we found that adalimumab in combination with azathioprine increased trough levels of adalimumab. Higher trough levels of adalimumab associated with endoscopic response and mucosal healing at Weeks 26 and 52. UMIN registration No: 000005146.
引用
- Watanabe K, Matsumoto T, Hisamatsu T, et al. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2017. PMID: 29104132. doi:10.1016/j.cgh.2017.10.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。